Provigil – Modafinil Information

The pharmaceutical industry is no stranger to dirty tricks and shady dealings in a bid to keep its customers coming back time and again. Although they would prefer to call it “just doing business”.

Indeed shifting patients from a soon-to-go-off-patent blockbuster, to its tweaked successor is old hat in the pharma biz.

Ever since drugmakers figured out that adding a time-release coating or other slight improvement could earn it a new round of patent protection, they’ve been developing strategies for competing against their own meds.

Raising the price of the old version to get patients to switch to the new brand, hoping they’ll stick when the old one goes generic? Done.

Read the rest of this entry »

Although generic modafinil has been available for some time from one or two pharmacies, the rest of the industry is now up in arms over what its calling the “Cephalon conspiracy”, in which the US drug manufacturer is accused of striking a $200 million deal to keep generic drug makers away from Provigil.

Cephalon conspired with other drug makers to delay generic competition for its blockbuster drug Provigil, pharmacy chains say in a federal antitrust class action.

Read the rest of this entry »

A Facebook group which is aimed at answering questions regarding Cephalon’s Provigil/Modafinil anti-narcolepsy drug is proving popular with consumers who have been prescribed other stimulants such as Ritalin, but who would prefer to use Provigil/Modafinil. A drug which has a far more benign effect on the human dopamine receptors.

Ritalin is a heavily prescribed (and even more heavily abused) amphetamine based drug normally prescribed in the treatment of ADD/ADHD amongst a great many others.

And whilst I’m no doctor or pharmacist, I have read a great deal into the workings of how it affects the human body, and how it works has no resemblence at all, to how Provigil works.

Read the rest of this entry »

Advocates say they are an irresistible way of improving students’ performance. Critics argue they are a dangerous fad. Jeremy Laurance explores the debate.

In the middle of the exam season, the offer of a drug that could improve results might excite students but would be likely to terrify their parents.

Now, a distinguished professor of bioethics says it is time to embrace the possibilities of “brain boosters” – chemical cognitive enhancement. The provocative suggestion comes from John Harris, director of the Institute for Science, Ethics and Innovation at the University of Manchester, and editor-in-chief of the Journal of Medical Ethics.

Read the rest of this entry »